Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2019 / Cilt: 24 - Sayı: 2

Multicenter Analysis of Anidulafungin Use in Invasive Candida Infections

İnvaziv Kandida İnfeksiyonlarında Anidulafungin Kullanımının Çok Merkezli Analizi

Pages
136–142
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We observed that anidulafungin is an effective and safe choice in invasive candida infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Fungal infections are vital problems worldwide and their incidence have increased along with changing patient profile.
📊
Key Findings & Data:Materials and Methods: In the first three years (1 January 2012 to 31 December 2014) when anidulafungin came out in our country, we retrospectively evaluated the data of the patients with invasive candida infections who were treated by anidulafungin for more than 48 hours in seven university hospitals.
💡
Conclusion & Impact:We observed that anidulafungin is an effective and safe choice in invasive candida infections.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Fungal infections are vital problems worldwide and their incidence have increased along with changing patient profile. Particularly candida species is still the most commonfungal agent, and the significance of non-albicans candida species have gained importance in recent years. In the present study, it was aimed to evaluate retrospectively the risk factors and distribution of candida species in patients with invasive candida infections, who were treated with anidulafungin. Materials and Methods: In the first three years (1 January 2012 to 31 December 2014) when anidulafungin came out in our country, we retrospectively evaluated the data of the patients with invasive candida infections who were treated by anidulafungin for more than 48 hours in seven university hospitals. Data were recorded to the case report forms. Results: Two hundreds and fifty-seven patients were included into the study. Fifty-six percent of the patients were male and mean age was 58.57 ± 19.5 years. Two hundreds and three patients (79%) were hospitalized in intensive care units, 37 (14.3%) in internal medicine services, and 17 (0.07%) in surgery services. As previously described, we detected antibiotic usage in the last month (%96.9), presence of urinary catheter (90.3%) and presence of central venous catheter (82.1%) as risk factors for invasive candida infections. More than half of the patients (57.1%) with central venous catheter had candidemia. Sixty-six (47.7%) of the blood isolates were Candida albicans, 33 (23.7%) were Candida parapsilosis, 17 (12.2%) were Candida tropicalis and 13 (9.4%) were Candida glabrata. During follow up, 64.5% of 124 patients whose catheters couldn’t be taken off and 47.6% of 86 patients whose catheters could be taken off died. During anidulafungin treatment, one anaphylaxis, one skin eruption and one thrombocytopenia were seen as side effects. Conclusion: In our study, we found that removal of central venous catheter of the patients with candidemia was a positive effect on mortality. We suggest that patients with candidemia, insisting on catheter removal besides antifungal treatment is necessary. We observed that anidulafungin is an effective and safe choice in invasive candida infections.

Özet

Giriş: Tüm dünyada fungal infeksiyonlar önemli bir sorun olup değişen hasta profili ile birlikte sıklığı artmıştır. Özellikle kandida halen en sık karşılaşılan fungal etken olup son yıllarda albikans dışı kandidaların önemi artmıştır. Bu çalışmada, invaziv kandida infeksiyonu nedeniyle tedavi edilen hastaların gerçek yaşam verileriyle anidulafunginin etkinliğinin ve yan etkilerinin retrospektif olarak değerlendirilmesi amaçlanmıştır. İkincil amaç hastaların risk faktörlerinin değerlendirilmesidir. Materyal ve Metod: Yedi üniversite hastanesinde 1 Ocak 2012-31 Aralık 2014 tarihleri arasında invaziv fungal infeksiyon tanısı ile 48 saatten daha uzun süre anidulafungin tedavisi alan hastaların verileri retrospektif olarak değerlendirildi. Veriler oluşturulan formlara kaydedildi. Bulgular: Çalışmaya yedi merkezden toplam 257 hasta dahil edilmiştir. Hastaların 144 (%56)’ü erkek, yaş ortalaması 58.6 ± 19.5 yıldı. Hastaların 137 (%53.3)’si dahili bölümlerde [100 (%72.9)’ü yoğun bakım], 120 (%46.7)’si cerrahi bölümlerde [103 (%85.3)’ü yoğun bakım] idi. Hastalarda tanımlanmış risk faktörü olarak son bir ayda antibiyotik kullanımı, üriner kateterizasyon ve santral venöz kateter varlığı saptanmıştır. Santral venöz kateter 210 (%82.7) hastada vardı. Santral venöz kateteri olan hastaların 120 (%57.1)‘sinde kan kültürü pozitifti. Kateteri çekilen 86 hastanın 41 (%47.6)’inin, çekilmeyen 124 hastanın 80 (%64.5)’inin mortalite ile sonuçlandığı görülmüştür. Kan kültüründe üreyen etkenlerin %47.7’si Candida albicans , %23.7’si Candida parapsilosis, %12.2’si Candida tropicalis idi. Anidulafungin tedavisi boyunca bir hastada anafilaksi, bir hastada cilt erüpsiyonu, bir hastada ise trombositopeni yan etkisi görülmüştür. Sonuç: Çalışmamızda kateter kaynaklı kandidemi olgularında kateterin çıkarılmasının gerekliliği vurgulanmaktadır. Ayrıca anidulafunginin etkin ve yan etkilerinin az olduğu izlenmekle birlikte diğer ekinokandinlerle karşılaştırmalı prospektif çalışmalara ihtiyaç duyulmaktadır.

🔖

Cite This Article

TAŞBAKAN, M. I., KUTSOYLU, O. E., PULLUKÇU, H., KUTLU, S. S., ÖZTÜRK, B., KAYA, O., TURHAN, Ö., AKAT, Ş. Ş., ÇAVUŞ, S. A., KUTLU, M., MERMUT, G., METİN, D. Y., ÖZHAK, B., ERGİN, Ç., ÇETİN, Ç. B., ERTUĞRUL, M. B., OĞUZ, V. A., YAPAR, N. (2019). Multicenter Analysis of Anidulafungin Use in Invasive Candida Infections. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 24 - Sayı: 2, 136–142. https://ajindex.com/articles/224352

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013;41:645-53.
  2. Yenigün Koçak B, Kuloğlu F, Doğan Çelik A, Akata F. Evaluation of epidemiological characteristics and risk factors of candidemia in adult patients in a tertiary-care hospital. Mikrobiyol Bul 2011;45:489-503.
  3. Yapar N, Pullukcu H, Avkan-Oguz V, Sayin-Kutlu S, Ertugrul B, Sacar S, et al. Evaluation of species distribution and risk factors of candidemia: A multicenter case-control study. Medical Mycology 2011;49:26-31. Küçükoğlu K. Antifungal tedavide son gelişmeler. Ankara Eczacılık Fakültesi Dergisi 2008;37:63-90.
  4. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. National Epidemiology of Mycoses Survey (NEMIS) Study Group. Risk factors for candidal bloodstream infections in surgical intensive care unit patients the NEMIS prospective multicenter study. The National Epidemiology of Mycoses Survey. Clin Infect Dis 2001;15:177- 86. Patolia S, Kennedy E, Zahir M, Patolia S, Gulati N, Narendra D, et al. Risk factors for candida blood stream infection in medical ICU and role of colonization: a retrospective study. BJMP 2013;6:a618. Ergin F, Tülek N, Yetkin MA, Bulut C, Oral B, Tuncer Ertem G. Yoğun bakım ünitesinde yatan hastalarda Candida kolonizasyonunun değerlendirilmesi ve kolonizasyon indeksinin kullanılması. Mikrobiyol Bul 2013;47:305-17.
  5. Leroy G, Lambiotte F, Thévenin D, Lemaire C, Parmentier E, Devos P, et al. O. Evaluation of “Candida score” in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care 2011;30:50. Al-Dorzi HM, Sakkijha H, Khan R, Aldabbagh T, Toledo A, Ntinika P, et al. Invasive candidiasis in critically ill patients: a prospective cohort study in two tertiary care centers. J Intensive Care Med 2018;1:885066618767835. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers 2018;11:18026. Dalyan Cilo B, Topaç T, Ağca H, Sağlam S, Efe K, Ener B. Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates. Mikrobiyol Bul 2018;5:35-48.
  6. Seyedmousavı S, İlkit M, Durdu M, Ergin Ç, Hilmioğlu-Polat S, Melchers W, et al. Candida ve kandidoz: e